C4XD signs exclusive global licence worth up to $402 million1 with AstraZeneca for the development and commercialisation of NRF2 Activator programme C4XD is eligible to receive upfront and pre-clinical payments of $16 million, plus development and commercial milestones, and tiered mid-single digit royalties Agreement further substantiates C4XD's scientific expertise and strategy through a third significant deal with a major pharmaceutical company MANCHESTER, ENGLAND / ACCESSWIRE / November 28, 2022 / C4X Discovery Holdings plc (AIM:C4XD), a pioneering Drug Discovery company, has signed an exclusive worldwide licensing agreement with AstraZeneca worth up to $402 million1, for its NRF2 Activator programme. AstraZeneca will develop and commercialise an oral therapy for the treatment of inflammatory and respiratory diseases with a lead focus on chronic obstructive pulmonary disease (COPD).